ANDA 65005, held by Impax Laboratories. Minocycline Hydrochloride.
As of Nov 22, 2026, ANDA 65005 (Minocycline Hydrochloride), held by Impax Laboratories, was first approved by FDA on Mar 23, 1999, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 23, 1999 | Original application | Approved |
| Minocycline HydrochlorideEQ 50MG BASE · capsule;oral | Minocycline Hydrochloride | Rx |
| Minocycline HydrochlorideEQ 100MG BASE · capsule;oral | Minocycline Hydrochloride | Rx |
| Minocycline HydrochlorideEQ 75MG BASE · capsule;oral | Minocycline Hydrochloride | Rx |
| Jun 15, 2011 | Supplement 11Labeling | Approved | None posted |
| Apr 19, 2004 | Supplement 8Labeling | Approved | None posted |
| Apr 13, 2004 | Supplement 7Labeling | Approved | None posted |
| Dec 6, 2001 | Supplement 4Manufacturing | Approved | None posted |
| Apr 18, 2001 | Supplement 1Manufacturing | Approved | None posted |
| Apr 18, 2001 | Supplement 2Manufacturing | Approved | None posted |
| Apr 18, 2001 | Supplement 3Labeling | Approved | None posted |
| Mar 23, 1999 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters